Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Grant Revenue	$ 109,745	$ 69,733	$ 602,808	$ 436,600
Operating Expenses:
Research and development	413,987	350,792	1,442,449	1,333,399
General and administrative	651,486	433,089	1,358,206	1,399,765
Total Operating Expenses	1,065,473	783,881	2,800,655	2,733,164
Total Operating Loss	(955,728)	(714,148)	(2,197,847)	(2,296,564)
Other Income/(Expense):
Research and development tax credit	56	(167)	9,357	15,798
Interest expense, net	(58,679)	(61,524)	(176,751)	(157,589)
Total Other Expense, Net	(58,623)	(61,691)	(167,394)	(141,791)
Net Loss	$ (1,014,351)	$ (775,839)	$ (2,365,241)	$ (2,438,355)
Loss Per Common Share - basic	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.01)
Loss Per Common Share - diluted	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.01)
Weighted Average Number of Common Shares Outstanding - basic	419,906,732	419,515,869	419,651,259	419,503,438
Weighted Average Number of Common Shares Outstanding - diluted	419,906,732	419,515,869	419,651,259	419,503,438

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.